Status:
UNKNOWN
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
Lead Sponsor:
Shengjing Hospital
Collaborating Sponsors:
Liaoning Cancer Hospital & Institute
The People's Hospital of Liaoning Province
Conditions:
Breast Cancer
Eligibility:
FEMALE
55-70 years
Brief Summary
Triple-negative breast cancer has a poor prognosis and lacks effective adjuvant treatment. A number of preclinical and clinical trials have shown that bisphosphonates have direct or indirect anti-tumo...
Detailed Description
Triple-negative breast cancer lacks expression of estrogen receptor, progesterone receptor, and proto-oncogene HER2 as shown by immunohistochemical examination. Its incidence accounts for 15-25% of th...
Eligibility Criteria
Inclusion
- developing breast cancer as confirmed by X-ray examination, and cancer tissue was negative for estrogen receptor, progesterone receptor and HER2
- presence of metastatic axillary lymph nodes
- standardized adjuvant therapy
- age over 55 years
Exclusion
- pregnant or lactating women
- those allergic to bisphosphonates
- those who are participating in other trials
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04045522
Start Date
September 1 2019
End Date
August 31 2022
Last Update
July 20 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
2
Liaoning Tumor Hospital & Institute
Shenyang, Liaoning, China
3
People's Hospital of Liaoning Province
Shenyang, Liaoning, China